Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists

Clinical Rheumatology

Volumn 34, Issue 8, 2015, Pages 1427-1433

  Grabowski, David ^a   Henderson, Bradley ^a   Lam, Dennis ^a   Keystone, Edward C ^b   Thorne, Carter ^c   Jamal, Shahin ^d   Pope, Janet ^e   Haraoui, Boulos ^f   Lin, Daming ^b   Revers, Leigh ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f NOTRE DAME HOSPITAL   (Canada)

Author keywords

Biosimilars; Rheumatology; Subsequent entry biologics; Survey

Indexed keywords

BIOSIMILAR AGENT; BIOLOGICAL PRODUCT;

ARTICLE; HEALTH SURVEY; HUMAN; KNOWLEDGE; MEDICAL PRACTICE; NORMAL HUMAN; PHARMACIST; PHYSICIAN; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; RHEUMATOLOGY; WORK EXPERIENCE; CANADA; CLINICAL PRACTICE; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; RHEUMATIC DISEASES;

ATTITUDE OF HEALTH PERSONNEL; BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; CANADA; HEALTH CARE SURVEYS; HUMANS; PRACTICE PATTERNS, PHYSICIANS'; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 84938739042     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2835-4     Document Type: Article

References (24)

1. Upchurch KS, Kay J (2012) Evolution of treatment of rheumatoid arthritis. Rheumatology 51:vi28–vi36
2. Revers L, Furczon E (2010) An introduction to biologics and biosimilars. Part II: Subsequent Entry Biologics: Biosame or Biodifferent? Can Pharm J 143:184-191
3. Scheinberg MA, Kay J (2012) The advent of biosimilar therapies in rheumatology — “O brave new world.” Nat Rev Rheumatol 8:430–436
4. Schiestl M, Stangler T, Torella C, Čepeljnik T, Toll H, Grau R (2011) Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nature Biotechnol 29:310–312
5. Kay J, Feagan BG, Guirguis MS, Keystone EC, Klein AV, Lubiniecki AS, Mould DR, Nyarko KA, Ridgway AAG, Trudeau ME, Wang J (2012) Health Canada/BIOTECanada Summit on Regulatory and Clinical Topics Related to Subsequent Entry Biologics (Biosimilars), Ottawa, Canada, 14 May 2012. Biologicals 40:517–527
6. Farfan-Portet MI, Gerkens S, Lepage-Nefkens I, Vinck I, Hulstaert F (2014) Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ 15:223
7. Dörner TSV, Castañeda-Hernández G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72:322–328
8. Papp K, Bourcier M, Ho V, Burke V, Haraoui B (2013) Preparing for subsequent entry biologics in dermatology and rheumatology in Canada. J Cutan Med Surg 17:340–346
9. Ndegwa S, Quansah K. Subsequent entry biologics – Emerging trends in regulatory and health technology assessment frameworks [Environmental Scan, Issue 43, ES0284]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2014
10. Haustein R, de Millas C, Höer A, Häussler H (2012) Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiat J, 1(3-4):120–126
11. Ontario Rheumatology Association (2012) Position paper on subsequent entry biologics/biosimilars
12. Russell AS, Vandana A, Barnabe C, Jamal S, Offer RC, Olszynski WP, Shojania K, Haraoui B (2012) Subsequent entry biologics/biosimilars: A viewpoint from Canada. Clin Rheumatol 31:1289–1292
13. Canadian Dermatology Association (2013) Canadian Dermatology Association Position Statement: Biosimilars
14. Devlin SM, Bessler B, Bernstein CN, Fedorak RN, Bitton A, Singh H, Feagan BG (2013) Overview of subsequent entry biologics for management of inflammatory bowel disease and Canadian Association of Gastroenterology statement on subsequent entry biologics. Can J Gastroenterol 27:567–571
15. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ureña S, Lim M, Lee YA, Kim H, Yoo DH, Braun J (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study. Ann Rheum Dis 72:1605–1612
16. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, Kovalenko V, Prodanovic N, Abello-Banfi M, Gutierrez-Ureña S, Morales-Olazabal L, Tee M, Jimenez R, Zamani O, Lee SJ, Kim H, Park W, Müller-Ladner U (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study. Ann Rheum Dis 72:1613–1620
17. Health Canada Food and Drugs Branch (2010) Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs). Health Canada, Ottawa, Canada
18. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre EB, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanoc B, Son YK, Park W, Muller-Ladner U. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: Comparison between continued CT-P13 and switching from infliximab to CT-P13. Abstract presented at: Annual Meeting of the American College of Rheumatology; 26-29 October 2013; San Diego, CA
19. Health Canada Food and Drugs Branch (2010) Questions & Answers to Accompany the Final Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs). Health Canada, Ottawa, Canada
20. Colbert RA, Cronstein BN (2011). Biosimilars: the debate continues. Arthritis Rheum 63:2848–2850
21. Haraoui B, Bensen W, Bessette L, Le Clercq S, Thorne C, Wade J (2012) Treating rheumatoid arthritis to target: A Canadian physician survey. J Rheumatol 39:949–953
22. National Physician Survey (2013) 2013 National Physician Survey (NPS): Demographics for internal medicine specialists. National Physician Survey, Mississauga
23. National Physician Survey (2010) 2010 National Physician Survey (NPS): Demographics for internal medicine specialists. National Physician Survey, Mississauga
24. Nederhof AJ (1985) Methods of coping with social desirability bias: A review. Eur J Soc Psychol 15:263–280